Skip to main content

View full-text article in PMC

. 2017 Apr 11;57(8):988–996. doi: 10.1002/jcph.887

Table 4.

Effect of Ozanimod 1.5 mg/d on Lymphocyte Subsets on Days 28 and 42

		Ozanimod (n = 4)		Placebo (n = 2)
Lymphocyte Subtype	Phenotype^a	% Change on Day 28^b	% Change on Day 42^c	% Change on Day 28^b	% Change on Day 42^c
Naive T cells	CD4⁺ CCR7⁺ 45RA⁺	−86	−38	+8	+7
Central memory	CD4⁺ CCR7⁺ 45RO⁺	−88	−52	+8	−6
TEMRA	CD4⁺ CCR7^‐ 45RA⁺	−3	+54	+35	+66
Effector memory	CD4⁺ CCR7^‐ 45RO⁺	−69	−41	−19	−5
Naive T cells	CD8⁺ CCR7⁺ 45RA⁺	−85	−40	+51	+51
Central memory	CD8⁺ CCR7⁺ 45RO⁺	−83	−55	+58	+34
TEMRA	CD8⁺ CCR7⁻ 45RA⁺	+7	−6	+58	+53
Effector memory	CD8⁺ CCR7^‐ 45RO⁺	−39	−33	+22	+29
Total T cells	CD3⁺ CD20^‐	−68	−39	−5	−7
B cells	CD3⁻ CD20⁺	−77	−49	−3	0
Natural killer cells	CD3⁻ CD16/56⁺	+18	+2	+33	−9

TEMRA, subset of effector memory T cells that are 45RA positive.

^aEvaluated by flow cytometry.

^bMean percent change in cell count on day 28 relative to pretreatment.

^cMean percent change in cell count following 14‐day recovery.